CY1110941T1 - Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας - Google Patents

Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας

Info

Publication number
CY1110941T1
CY1110941T1 CY20101101060T CY101101060T CY1110941T1 CY 1110941 T1 CY1110941 T1 CY 1110941T1 CY 20101101060 T CY20101101060 T CY 20101101060T CY 101101060 T CY101101060 T CY 101101060T CY 1110941 T1 CY1110941 T1 CY 1110941T1
Authority
CY
Cyprus
Prior art keywords
hip
pap
amino acid
polypeptide
mitogenic
Prior art date
Application number
CY20101101060T
Other languages
English (en)
Inventor
Laurence Christa
Christian Brechot
Marie-Thérèse SIMON-GAGE-SOUFFLOT
Alain Pauloin
J Guilherme Tralhao
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of CY1110941T1 publication Critical patent/CY1110941T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση βασίζεται στο πειραματικό εύρημα ότι ΗΙΡ/ΡΑΡ έχει μιτογονικά και αντι-αποπτωτικά αποτελέσματα in vitro επί ηπατοκυττάρων σε πρωτογενή καλλιέργεια. Επιπλέον, ΗΙΡ/ΡΑΡ είναι μιτογονικό και αντι-αποπτωτικό μόριο για ηπατοκύτταρα, in vivo, κατά τη διάρκεια ηπατικής ανεπάρκειας και αναγέννησης ήπατος. Η παρούσα εφεύρεση βασίζεται επίσης στο πειραματικό εύρημα ότι χορήγηση ΗΙΡ/ΡΑΡ δεν έχει αντίθετα αποτελέσματα σε θηλαστικά. Η εφεύρεση αυτή αφορά φαρμακευτική σύνθεση για διέγερση αναγέννησης ήπατος in vivo, συμπεριλαμβανομένης μετά από χρόνια/οξεία ηπατική ανεπάρκεια, περιλαμβάνουσα αποτελεσματική ποσότητα ενός πολυπεπτιδίου που περιλαμβάνει αλληλουχία αμινοξέος που έχει 90% ταυτότητα αμινοξέος με το πολυπεπτίδιο που συνίσταται από την αλληλουχία αμινοξέος που ξεκινά στο υπόλειμμα αμινοξέος (36) και τερματίζεται στο υπόλειμμα αμινοξέος (175) της αλληλουχίας SEQ ID Ν°1, σε συνδυασμό με τουλάχιστον ένα φυσιολογικώς αποδεκτό έκδοχο.
CY20101101060T 2003-06-18 2010-11-24 Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας CY1110941T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03291487A EP1488798A1 (en) 2003-06-18 2003-06-18 HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
EP04740077A EP1638594B1 (en) 2003-06-18 2004-06-18 Hip/pap polypeptide composition for use in liver regeneration and for the prevention of liver failure

Publications (1)

Publication Number Publication Date
CY1110941T1 true CY1110941T1 (el) 2015-06-10

Family

ID=33396036

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101060T CY1110941T1 (el) 2003-06-18 2010-11-24 Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας

Country Status (15)

Country Link
US (2) US20060276388A1 (el)
EP (2) EP1488798A1 (el)
JP (1) JP4709141B2 (el)
CN (1) CN1835764B (el)
AT (1) ATE480254T1 (el)
AU (1) AU2004248914B2 (el)
CA (1) CA2529896C (el)
CY (1) CY1110941T1 (el)
DE (1) DE602004029038D1 (el)
DK (1) DK1638594T3 (el)
ES (1) ES2351893T3 (el)
PL (1) PL1638594T3 (el)
PT (1) PT1638594E (el)
SI (1) SI1638594T1 (el)
WO (1) WO2004112824A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1488798A1 (en) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
EP1900749A1 (en) 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells
US7923014B2 (en) * 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
EP2260857A1 (en) * 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
WO2011003098A1 (en) * 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US8893292B2 (en) 2012-11-14 2014-11-18 Mitsubishi Electric Research Laboratories, Inc. Privacy preserving statistical analysis for distributed databases
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
RU2559935C1 (ru) * 2014-06-10 2015-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ стимуляции регенерации резецированной печени l-аргинином
RU2590859C1 (ru) * 2015-06-30 2016-07-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Способ дистантной стимуляции регенерации гепатоцитов
RU2601160C1 (ru) * 2015-07-09 2016-10-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОмГМУ Минздрава России) Способ резекции печени у мелких лабораторных животных
ES2983978T3 (es) * 2016-01-08 2024-10-28 Univ Kyoto Medicina que comprende ADAMTS13 como ingrediente principal
RU2636194C1 (ru) * 2016-11-23 2017-11-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ стимуляции репаративной регенерации печени после ее резекции
CN107936111B (zh) * 2017-12-16 2021-09-07 广州安辰新药研究院有限公司 一种hip/pap蛋白的制备方法
CN114702550B (zh) * 2018-09-18 2023-09-12 广州领晟医疗科技有限公司 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途
CN110669126B (zh) * 2019-10-23 2022-08-16 广州领晟医疗科技有限公司 多肽gpr5及其促进肝细胞增殖和抑制肝细胞凋亡的用途
CN110627866B (zh) * 2019-10-23 2022-10-18 广州领晟医疗科技有限公司 多肽rly4及其促进肝再生和抑制肝细胞凋亡的用途
EP4262976A1 (en) * 2020-12-21 2023-10-25 Flagship Pioneering Innovations V, Inc. Use of cell turnover factors for increasing tissue regeneration
EP4085922A1 (en) 2021-05-07 2022-11-09 The Healthy Aging Company Hip/pap protein or a derivative thereof for treating peripheral neuropathy
CN113528639B (zh) * 2021-06-04 2023-06-13 南方医科大学南方医院 一组预测慢加急性肝功能衰竭预后的标志物及其应用
EP4252766A1 (en) 2022-04-01 2023-10-04 The Healthy Aging Company Hip/pap protein or a derivative thereof for treating and/or preventing a disorder characterized by a high cxcl5 serum level in an individual
CN114887036B (zh) * 2022-05-12 2026-02-10 中南大学湘雅二医院 抗菌肽在制备对乙酰氨基酚诱导的急性肝损伤和/或肝衰竭治疗制剂中的应用
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure
CN116004825B (zh) * 2022-12-08 2024-12-31 上海交通大学医学院附属上海儿童医学中心 Reg3a在制备辅助诊断或治疗肝母细胞瘤的试剂或药物中的应用
EP4464330A1 (en) 2023-05-17 2024-11-20 The Healthy Aging Company Hip/pap protein or a derivative thereof for treating a cognitive disorder associated with anxiety disorder
WO2024236159A1 (en) 2023-05-17 2024-11-21 The Healthy Aging Company Hip/pap protein or a derivative thereof for treating a cognitive disorder associated with anxiety disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661187B1 (fr) * 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
FR2700011B1 (fr) * 1992-12-24 1995-02-24 Inst Nat Sante Rech Med Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.
EP1488798A1 (en) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure

Also Published As

Publication number Publication date
US20110144036A1 (en) 2011-06-16
PT1638594E (pt) 2010-12-03
JP2006527733A (ja) 2006-12-07
EP1638594A1 (en) 2006-03-29
ES2351893T3 (es) 2011-02-11
JP4709141B2 (ja) 2011-06-22
CN1835764A (zh) 2006-09-20
PL1638594T3 (pl) 2011-08-31
DE602004029038D1 (de) 2010-10-21
SI1638594T1 (sl) 2011-03-31
EP1638594B1 (en) 2010-09-08
US20060276388A1 (en) 2006-12-07
DK1638594T3 (da) 2010-12-20
CA2529896A1 (en) 2004-12-29
AU2004248914B2 (en) 2010-02-25
WO2004112824A1 (en) 2004-12-29
ATE480254T1 (de) 2010-09-15
AU2004248914A1 (en) 2004-12-29
CN1835764B (zh) 2014-07-09
US8329661B2 (en) 2012-12-11
CA2529896C (en) 2014-02-11
EP1488798A1 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
CY1110941T1 (el) Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας
ES2505695T3 (es) Composiciones inmunógenas para Streptococcus pyogenes
PE20071063A1 (es) Formulaciones de proteinas estables
PE20100253A1 (es) Mutantes de fgf21
CY1106995T1 (el) Αμφιφιλα λιπιδικα νανοσωματιδια για ενσωματωση σε πεπτιδιο ´η/και πρωτεïνη
CY1113537T1 (el) Οξινα σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
ATE272654T1 (de) Neue vernetzte derivate der hyaluronsäure.
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
RU2012106150A (ru) Вариантные формы уратоксидазы и их применение
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CY1115918T1 (el) Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
SE0002202D0 (sv) New peptides
JP2010536714A5 (el)
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
BR0314450A (pt) Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
CA2504377A1 (en) Pharmaceutical preparation of recombinant factor viii lyophilized without albumin as a stabilizer
BR112022006926A2 (pt) Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2)
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)